Trial Profile
Idiopathic sudden sensorineural hearing loss treatment by Infliximab injection (TNF-alfa blocker)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2014
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Sudden hearing loss
- Focus Therapeutic Use
- 08 Jul 2014 New trial record